ALSO NOTED: Millipore CEO gains $3.9M comp package;Terminal cancer patients enlisted in trials; and much more...

> It may not rival the big bucks earned by Big Pharma CEOs, but Millipore chief exec Martin Madaus took home a hefty pay package last year. He earned $3.9 million in compensation in 2007. That includes $742,307 in base pay, a bonus of $488,000 and options worth $2.6 million on the day they were granted. Report

> Which drug exec gets paid 140 percent more than the median among his peers? Cephalon CEO Frank Baldino (photo). He made a cool $13.5 million last year. That paycheck included a $1.2 million salary, $2.2 million in bonus, and $10.1 million in stock and options. Report

> Mortality rates at 494 hospitals around the country that participated in clinical trials for acute coronary syndrome declined. Report

> Frustrated by the long years of research needed to prove the effectiveness of a new cancer therapy, British officials have designated a network of 19 hospital units that will be allowed to administer early-stage experimental cancer drugs to terminal patients. Report

> Big Pharma companies are often quick to turn their backs on a drug that doesn't deliver strong data. But a series of these failed development programs have been resurrected by scientists who decided to search for the kind of genetic biomarkers that would define a group of patients who would respond positively. Report

> Manipulating insulin levels raises the level of the master gene-regulating protein SKN-1, significantly prolonging the lives of microscopic worms in one study. Report

> HistoRx and Eli Lilly have extended their technology agreement. Story

> Pfizer and GlaxoSmithKline have been marking up meds to increase their revenues, according to Thomson data. The two companies boosted wholesale prices by about 9 percent on their 10 best-sellers last year. Without those increases, Pfizer and GSK would have seen their sales drop by more than 10 percent. Report

> Pfizer is suing for Lipitor protection until 2016. Report

And Finally... Many in the medical community are at odds over the ethics of at-home bipolar gene tests currently on the market. Report

Suggested Articles

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.